Member Info for Scinv_temp

These are the next steps as I see them:

Company says at some point that they had some interest from pharma but they asked for data specifically for the indication they are after. Meaning that for flu for example they would have to do a phase 2 specifically to prevent/treat flu complications. Because otherwise, why would they fund somebody elses asset when the could be funding their own?

This means they will have to do a placing, get millions from investors and then plan and execute said phase 2 for the next 2 years or so.

If that trial shows something others have not seen before (and they have tried) then they will have a chance at getting something out of it, maybe 2-3 times cost of trial and single digit royalties from sales if aforementioned pharma actually gets to approval.

Another scenario is they outlicence to another small biotech or fund for 500k to 1M and low single digit royalties if the other party actually gets to the finish line.

These are the only good scenarios that I can see.

The bad one (and it does happen) is they ask millions from investors, spend half for a sloppy phase 2 and use the rest to keep the company going for a few more years.

Imho

Are you the one who lied about being a medic? You know pretending to be a health professional is illegal regardless of the context. I do apologise if that wasn't you, remember someone suggesting they were in a comversation in which you participated as well, but not sure if it was you.

In any case, do you have anything to say about the facts I posted?

At this point this is an IQ test, but let me make it more clear. When JS talked about longer treatment he specifically mentioned arthritis, alzheimers etc. The studies I posted now (and previosuly) that explore the usefulness in respiratory viral infections, or other non chronic inflamation conditions, they obviously (duh!) use or suggest shorter treatments. Polb has done nothing new and this is a *FACT*.

In for respiratory viruses they werent. For arthritis and a few for alzheimers lmao

That is exactly right you troll

Moniman 199 posts last 30 days
Scinv_temp 22 post last 30 days

It's a fat banana "behind" the punters who invest any significant amount of money here

You said polb001 is worth over 100M, will you even apologise for those you drag with you into?

I only have one ID, no association to polb and I post facts instead of blarney

So what? Lmao

The truth is you are been taken for a ride.

I have previoualy posted the numerous p38i out there that pretty much every big pharma has on the shelf.

I have also posted numerous studies that show biomarker modulation in response to p38 inhibitors and speculation on their potential role in complications in influenza and other viral infections, the vast majority of which took place long before hvivo (the original holder of polb patent on polb001) let alone polb.

A coulple of presentations back JS mentioned that their "patents" would prevent everyone else from using their own p38i which is so wrong (they can't stop anyone) its disgustingly unethical towards investors.

Now here 3 other clinical trials, 1 of which took place long before polb was even an idea, let alone a company.

Covid 19, same rational as with flu 2020
https://clinicaltrials.gov/ct2/show/NCT04394208
Similar as above
https://clinicaltrials.gov/ct2/show/NCT04511819?term=P38+mapk&draw=4&rank=28

Similar to the one polb did (lps human challenge) but from 2014
https://clinicaltrials.gov/ct2/show/NCT02211170?term=P38+mapk&draw=7&rank=51

So your answer is "huge". Got it. Will you even apologise to people who lose their money also because of the nonsense you, cashintime and others post here?

No it doesn't. This isn't the first or the tenth p38i that modulates those biomarkers. A good deal with pharma would prove me wrong. Just to cut through the bs here, what is your estimate on what polb001 is worth to the company?

This kind of nonsense is what gets people to lose their pensions in the stock msrket. Who exactly is going to be involved in a bidding war for an asset that pretty much everyone has?

I forgot to say, to think that any significant amount of shorting (if any at all) takes place here is laughable.

Any investor who is not a complete 1d1ot takes the opportunity to buy shares when a company is "under attack" by shorters if they believe in the fundamentals. Shorting cannot do anything to a good company in the long run. What suddens me here is I still see some of the same zealots here who still don't understand that this company is finished and they try to convimce others to lose money as well, little Tommy. Two years have past but you are still the same.

Do not expect anything from that. The business is challenge studies + bespoke readouts from said studies. The rest is nonsense and the only thing one achieves by talking asking about that is promoting expectations on nonsense that will never happen. Or, worst, forcing the company to spend good money on developing that nonsene.

The MMs, the illuminati and the bilderberg club want your shares. Sure.

You are going to hear a lot more of that and not m7ch beyond that. By the way, kissing the blarney stone maybe allows you to charm a fool, not serious pharma. Then again, my english is not very good apparently so maybe CF and JS are actually geniouses? Lmao

Sure cause if that happens (you see I gave you that one?) that's gonna make the divident make sense.

No, just the m0rons who can't tell the difference between mispellings and mistypings and then think they actually made a smart comment. Exactly those.

Only m0rons care about "distribution" from a comapny that barely has £25 in cash and over 650M issued shares. Distribution aas the only negative news issued lately and the main reason company is not taken seriously by the big players. Sadly, cf still seems to have a lot of influence as he is the one who promised this to the oldtimers invested here anyway.